PALO ALTO, Calif. and OSAKA, Japan , May 10, 2022 /PRNewswire/ -- Eiger Biopharmaceuticals Inc. (" Eiger ", Nasdaq: EIGR) and AnGes Inc. (" AnGes ", TYO: 4563) today announced that the companies entered into an agreement for the regulatory approval, marketing, and distribution of Zokinvy ®

Peginterferon lambda COVID-19 EUA Application to be Submitted in Q2 2022 Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Anticipated by Year End Zokinvy ® (lonafarnib) CHMP Opinion Expected in Q2 2022 Phase 3 Avexitide Congenital Hyperinsulinism Program Initiation Planned by Year End Strong Cash

PALO ALTO, Calif. , April 29, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today reported that the